Certificate Reference
For continuity with the current catalog, this page links to laboratory documentation for a component or a closely related product. The linked certificate is a reference only and is not represented as the batch-specific COA for CJC-1295 (With DAC).
Overview
CJC-1295 with DAC is the long-acting version of the GHRH analog, engineered with a reactive Drug Affinity Complex that binds circulating albumin and greatly extends exposure. This makes it useful for studying sustained stimulation of the GH/IGF-1 axis rather than short pulse-only signaling.
Research Reference: View identity reference
Research Focus
WHAT THIS FORMULA FEATURES
Albumin binding is the defining feature. In controlled human research, CJC-1295 produced sustained, dose-dependent elevations in GH and IGF-1 lasting for days, while preserving measurable pulsatile GH secretion.
EXPECTED RESEARCH READOUTS
Typical endpoints include multi-day GH and IGF-1 profiles, pulse frequency and amplitude, pharmacokinetic half-life, albumin binding, and cumulative endocrine response after repeated exposure. The long duration should be treated as a core experimental variable.
Research endpoints described above reflect published or model-based scientific observations and are not guaranteed outcomes. This product is strictly for research purposes only. Not approved for human or animal use.
Key Characteristics
MOLECULAR PROFILE
CAS: 446262-90-4
PubChem CID: 91971820
Classification: DAC-modified GHRH analogue
PHYSICAL PROPERTIES
Form: Lyophilized powder
Catalog strengths: 2 mg | 5 mg | 10 mg
Purity specification: ≥99% catalog specification; verify current batch COA
Storage: Store at −20°C (−4°F) for long-term storage or 4°C (39°F) for short-term storage; avoid repeated freeze-thaw cycles.
Testing: Batch documentation should be verified against the current lot before analytical use.
